BMO upgrades Genmab to outperform, cites diversification potential
https://seekingalpha.com/news/4071279-bmo-upgrades-genmab-to-outperform-cites-diversification-potential?source=feed_sector_healthcare
Feb 23, 2024 - BMO has upgraded Genmab (GMAB) to outperform, stating that it was “incrementally more confident” in the company’s ability to diversify its business longer term
0
BMO starts Korro at outperform, cites upcoming data for AATD drug
https://seekingalpha.com/news/4072585-bmo-starts-korro-at-outperform-cites-upcoming-data-for-aatd-drug?source=feed_sector_healthcare
Feb 27, 2024 - BMO initiated coverage of Korro Bio (KRRO) with an outperform rating, citing upcoming data for its AATD drug candidate KRRO-110 and potential partnerships. Read more here.
0
UWM Holdings Corporation (UWMC) Reports Break-Even Earnings for Q1
https://www.zacks.com/stock/news/2271494/uwm-holdings-corporation-uwmc-reports-break-even-earnings-for-q1?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271494
May 09, 2024 - UWM (UWMC) delivered earnings and revenue surprises of -100% and 22.13%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
0
Jefferies, BMO bullish on newly public Metagenomi
https://seekingalpha.com/news/4076822-jefferies-bmo-bullish-on-newly-public-metagenomi?source=feed_sector_healthcare
Mar 06, 2024 - Jefferies and BMO have initiated coverage of newly public Metagenomi (MGX) with bullish ratings, citing the company’s wide array of gene editing tools. Read more here.
0
Pages: 1
Page 1